pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
230
stories
May 29, 26
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
endpoints
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 28, 26
STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
stat
May 28, 26
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
endpoints
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 19, 26
STAT+: A new ranking of pharma companies by R&D performance
stat
May 19, 26
STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
stat
May 18, 26
STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
stat
May 14, 26
Makary’s departure and Cassidy’s tenuous Senate seat
stat
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
endpoints
May 12, 26
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
biopharma dive
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 11, 26
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
stat
May 8, 26
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
onclive
May 8, 26
Lilly to invest extra $4.5B across Indiana manufacturing
biopharma dive
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
May 7, 26
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
stat
May 7, 26
Angelini to buy Catalyst in $4B play for rare neuro drugs
biopharma dive
May 6, 26
Lilly plans new $4.5B manufacturing investment in Indiana
endpoints
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
biopharma dive
← prev
page 7 of 8
next →
